Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva and Alimta in progressive or recurrent NSCLC
NCT00950365Phase 2Completed
- Sponsor
- Albert Einstein College of Medicine
- Start
- Apr 2006
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Albert Einstein College of Medicine. Started Apr 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00950365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00950365.